- Home
- BIAF vs XXII Comparison
BIAF vs XXII Comparison
Compare BIAF & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- XXII
- Stock Information
- Founded
- BIAF 2014
- XXII 1998
- Country
- BIAF United States
- XXII United States
- Employees
- BIAF N/A
- XXII N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XXII Medicinal Chemicals and Botanical Products
- Sector
- BIAF Health Care
- XXII Health Care
- Exchange
- BIAF Nasdaq
- XXII Nasdaq
- Market Cap
- BIAF 7.6M
- XXII 6.2M
- IPO Year
- BIAF 2022
- XXII N/A
- Fundamental
- Price
- BIAF $3.24
- XXII $1.58
- Analyst Decision
- BIAF Hold
- XXII
- Analyst Count
- BIAF 1
- XXII 0
- Target Price
- BIAF N/A
- XXII N/A
- AVG Volume (30 Days)
- BIAF 7.6M
- XXII 3.6M
- Earning Date
- BIAF 11-13-2025
- XXII 11-11-2025
- Dividend Yield
- BIAF N/A
- XXII N/A
- EPS Growth
- BIAF N/A
- XXII N/A
- EPS
- BIAF N/A
- XXII N/A
- Revenue
- BIAF $7,681,059.00
- XXII $21,362,000.00
- Revenue This Year
- BIAF N/A
- XXII N/A
- Revenue Next Year
- BIAF $20.04
- XXII $126.57
- P/E Ratio
- BIAF N/A
- XXII N/A
- Revenue Growth
- BIAF 4.99
- XXII N/A
- 52 Week Low
- BIAF $2.34
- XXII $1.51
- 52 Week High
- BIAF $67.12
- XXII $613.86
- Technical
- Relative Strength Index (RSI)
- BIAF 53.34
- XXII 43.98
- Support Level
- BIAF $2.36
- XXII $1.59
- Resistance Level
- BIAF $7.29
- XXII $1.77
- Average True Range (ATR)
- BIAF 0.63
- XXII 0.15
- MACD
- BIAF -0.30
- XXII 0.02
- Stochastic Oscillator
- BIAF 23.73
- XXII 15.19
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.